295 related articles for article (PubMed ID: 29248595)
1. Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
Cobice DF; Livingstone DEW; McBride A; MacKay CL; Walker BR; Webster SP; Andrew R
Biochem Pharmacol; 2018 Feb; 148():88-99. PubMed ID: 29248595
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G
J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256
[TBL] [Abstract][Full Text] [Related]
3. Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.
Sigurjonsdottir HA; Andrew R; Stimson RH; Johannsson G; Walker BR
Eur J Endocrinol; 2009 Sep; 161(3):375-80. PubMed ID: 19549748
[TBL] [Abstract][Full Text] [Related]
4. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
[TBL] [Abstract][Full Text] [Related]
5. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
6. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
7. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
[TBL] [Abstract][Full Text] [Related]
8. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
9. 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets.
Swali A; Walker EA; Lavery GG; Tomlinson JW; Stewart PM
Diabetologia; 2008 Nov; 51(11):2003-11. PubMed ID: 18779947
[TBL] [Abstract][Full Text] [Related]
10. Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1.
Meyer A; Vuorinen A; Zielinska AE; Da Cunha T; Strajhar P; Lavery GG; Schuster D; Odermatt A
Biochem Pharmacol; 2013 May; 85(9):1370-8. PubMed ID: 23419873
[TBL] [Abstract][Full Text] [Related]
11. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.
Lavery GG; Zielinska AE; Gathercole LL; Hughes B; Semjonous N; Guest P; Saqib K; Sherlock M; Reynolds G; Morgan SA; Tomlinson JW; Walker EA; Rabbitt EH; Stewart PM
Endocrinology; 2012 Jul; 153(7):3236-48. PubMed ID: 22555437
[TBL] [Abstract][Full Text] [Related]
12. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa.
Jun YJ; Park SJ; Kim TH; Lee SH; Lee KJ; Hwang SM; Lee SH
J Allergy Clin Immunol; 2014 Oct; 134(4):926-934.e6. PubMed ID: 24810847
[TBL] [Abstract][Full Text] [Related]
13. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
14. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Stimson RH; Andersson J; Andrew R; Redhead DN; Karpe F; Hayes PC; Olsson T; Walker BR
Diabetes; 2009 Jan; 58(1):46-53. PubMed ID: 18852329
[TBL] [Abstract][Full Text] [Related]
15. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
Morris DJ; Latif SA; Hardy MP; Brem AS
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
[TBL] [Abstract][Full Text] [Related]
16. 11β-Hydroxysteroid dehydrogenase activity in the brain does not contribute to systemic interconversion of cortisol and cortisone in healthy men.
Kilgour AH; Semple S; Marshall I; Andrews P; Andrew R; Walker BR
J Clin Endocrinol Metab; 2015 Feb; 100(2):483-9. PubMed ID: 25393644
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation?
Sinclair AJ; Walker EA; Burdon MA; van Beek AP; Kema IP; Hughes BA; Murray PI; Nightingale PG; Stewart PM; Rauz S; Tomlinson JW
J Clin Endocrinol Metab; 2010 Dec; 95(12):5348-56. PubMed ID: 20826586
[TBL] [Abstract][Full Text] [Related]
18. Topical 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice.
Tiganescu A; Hupe M; Uchida Y; Mauro T; Elias PM; Holleran WM
Endocrinology; 2018 Jan; 159(1):547-556. PubMed ID: 29087473
[TBL] [Abstract][Full Text] [Related]
19. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.
Harno E; Cottrell EC; Yu A; DeSchoolmeester J; Gutierrez PM; Denn M; Swales JG; Goldberg FW; Bohlooly-Y M; Andersén H; Wild MJ; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Dec; 154(12):4580-93. PubMed ID: 24169553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
